NEW YORK, Feb. 5 - MDS Proteomics has acquired roughly 2,000 disease-related, full-length cDNA clones from Japan's Kazusa DNA Research Institute, MDS said on Tuesday.

The three-year deal "is a major step" to help MDS meet its goal of discovering 1,000 new drug targets in the next five years, according to Frank Gleeson, president and CEO of MDS Proteomics.

Financial terms of the agreement were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.